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functions as an extracellular matrix component. To determine the mechanisms underlying
NELL1-induced osteoblast differentiation, we examined the cell-adhesive activity of NELL1 using a
series of recombinant NELL1 proteins. We demonstrated that NELL1 promoted osteoblastic cell
adhesion through at least three cell-binding domains located in the C-terminal region of NELL1.
Adhesion of cells to NELL1 was strongly inhibited by function-blocking antibodies against integrin
a3 and b1 subunits, suggesting that osteoblastic cells adhered to NELL1 through integrin a3b1. Fur-
ther, focal adhesion kinase activation is involved in NELL1 signaling.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Osteogenesis proceeds through three major phases: (i) cell
proliferation, (ii) extracellular matrix (ECM) development and mat-
uration, and (iii) mineralization [1]. During the ﬁrst phase, mesen-
chymal progenitors are recruited to the bone-forming site where
they proliferate and differentiate into bone matrix-producing oste-
oblasts. These events are regulated by Runx2 (runt-related tran-
scription factor 2), a key transcriptional regulator of osteogenesis,
and are followed by the secretion of speciﬁc bone matrix proteins
such as type I collagen, bone sialoprotein, and osteocalcin. It has
been shown that the differentiation and maturation of osteoblasts
are regulated by their interaction with several other ECM proteins
[2–5]. These proteins are divided into two groups: structural pro-
teins such as laminin and ﬁbronectin, and matricellular proteins
such as tenascin-C and thrombospondin-1. Matricellular proteins
do not contribute directly to the formation of the structural
elements of the ECM, but rather serve to modulate cell-matrixchemical Societies. Published by E
atrix; EGF, epidermal growth
FAK, focal adhesion kinase;
terminal thrombospondin-1-
uroda), fax: +81 52 789 5237
uroda), tniimi@agr.nagoya-u.interactions and cell function through their interaction with cell
surface receptors such as integrins, and other components of the
ECM [6,7].
NELL1 is a secretory protein that exhibits potent osteoinductive
activity [8]. The NELL1 gene was originally identiﬁed in craniosyn-
ostosis patients as being speciﬁcally upregulated within prema-
turely fusing sutures [9]. The human NELL1 gene encodes a
polypeptide of 810 amino acids with structural similarities to
thrombospondin-1. It contains several structural motifs, including
an N-terminal thrombospondin-1-like (TSPN) domain (overlapping
with a laminin G domain), coiled-coil (CC) domain, four von
Willebrand factor type C (VWC) domains, and six epidermal growth
factor (EGF)-like domains (see Fig. 2A) [8]. Similar to thrombospon-
din-1, secreted NELL1 forms a homotrimer, presumably through a
coiled-coil domain [10]. NELL1 transduces osteogenic signals
through the Ras-mitogen-activated protein kinase (MAPK) pathway
and Runx2 [11]. We recently showed that recombinant NELL1 was
incorporated into the ECM following secretion from NELL1-
expressing cells, suggesting that NELL1 acts as an ECM component
[12]. However, the cell-binding activity of NELL1 and its cell surface
receptors have not yet been characterized.
In the present study, we utilized a series of recombinant NELL1
proteins to investigate whether NELL1 has cell-adhesive activity.
We demonstrated that NELL1 promoted osteoblastic cell adhesion
through at least three cell-binding sites localized to the C-terminal
region of NELL1. Function-blocking monoclonal antibodies identi-lsevier B.V. All rights reserved.
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adhesion onto NELL1. Furthermore, the focal adhesion kinase
(FAK)-MAPK pathway is involved in NELL1 signaling.2. Materials and methods
2.1. Antibodies and peptides
Function-blocking monoclonal antibodies to the human a1–6
and aV integrins (Alpha Integrin Blocking and IHC Kit), human
integrin b1 (6S6), human integrin b3 (25E11), and human integrin
b4 (3E1) were purchased from Millipore (Billerica, MA, USA). Rab-
bit polyclonal antibodies against human FAK, phospho-FAK
(Tyr397), human extracellular signal-regulated kinases (ERK) 1/2,
and phospho-ERK1/2 (Thr202/Tyr204) were purchased from Cell Sig-
naling Technology (Danvers, MA, USA). Rabbit polyclonal antibody
against human b-actin was purchased from GeneTex (Irvine, CA,
USA). The synthetic peptide GD-6 (KQNCLSSRASFRGCVRNLRLSR),
derived from mouse laminin a1 chain, was purchased from Ana-
spec (Fremont, CA, USA). The synthetic peptide CS1 (EILDVPST), de-
rived from type III homology connecting segment of ﬁbronectin,
was purchased from GenScript (Piscataway, NJ, USA).
2.2. Cell culture
The mouse pre-osteoblast cell line MC3T3-E1 (clone 4) was ob-
tained from RIKEN Cell Bank (Tsukuba, Japan), and was maintained
in a-minimum essential medium (MEM) containing 10% (v/v) fetal
calf serum (FCS). The human osteosarcoma Saos-2 and U2OS cell
lines were obtained from the Japanese Collection of Research Bio-
resources Cell Bank (Osaka, Japan), and were maintained in
McCoy’s 5A medium containing 10% (v/v) FCS. Mouse mesenchy-
mal C3H10T1/2 cells and the human osteosarcoma MG-63 cells
were also obtained from the Japanese Collection of Research Biore-
sources Cell Bank, and were maintained in Dulbecco’s modiﬁed Ea-
gle’s medium (DMEM) containing 10% (v/v) FCS. The human
ﬁbrosarcoma HT-1080 cell line was maintained in DMEM contain-
ing 10% (v/v) FCS. The human cervical carcinoma HeLa cell line was
maintained in MEM containing 10% (v/v) FCS.
2.3. Plasmid construction
Mammalian expression vectors for human NELL1 with N-termi-
nal FLAG- and C-terminal hexahistidine-tags were prepared as
follows: cDNA fragments encoding the N-(residues 17–272) or
C-(residues 273–810) terminal regions of human NELL1 were
ampliﬁed by polymerase chain reaction (PCR) from full-length
human NELL1 cDNA. The PCR products were digested with BamHI
and XhoI, and cloned into the pSecTag2-FLAG vector [13].
An expression vector for the C-terminal region of human NELL1
in Leishmania tarentolaewas prepared as follows: a cDNA encoding
the C-terminal region of human NELL1 (residues 273–810) was
ampliﬁed by PCR from the mammalian expression vector described
above. The PCR product was subcloned into the pCR-Blunt II-TOPO
vector (Invitrogen, Carlsbad, CA, USA), and the resultant plasmid
was digested with XbaI and NotI, and cloned into the pLEXSY-
Neo2 vector (Jena Bioscience, Jena, Germany) with a C-terminal
hexahistidine-tag.
Bacterial expression vectors for human NELL1 fragments were
prepared as follows: cDNAs encoding the TSPN and CC domains
(residues 17–272), the N-terminal VWC domains (residues 273–
388), the EGF-like domains (residues 389–634), and the C-terminal
VWC domains (residues 635–810) of human NELL1 were ampliﬁed
by PCR from full-length human NELL1 cDNA. The PCR products
were digested with HindIII and XbaI, and cloned into thepCold-TF vector (Takara Bio, Otsu, Japan). The resultant vectors ex-
press hexahistidine-tagged and trigger factor (TF)-fused proteins.
All primer sequences used in this study are available upon request.
2.4. Protein expression and puriﬁcation
Preparation of recombinant full-length NELL1 protein has been
described previously [12]. The recombinant N-terminal region of
NELL1 was produced using the FreeStyle MAX 293 Expression Sys-
tem (Invitrogen) according to the manufacturer’s instructions.
Brieﬂy, 293-F cells were transfected with the pSecTag2-FLAG-
hNELL1-N plasmid using the FreeStyle MAX Reagent (Invitrogen),
and grown in serum-free FreeStyle 293 Expression medium (Invit-
rogen) for 96 h. Recombinant protein was puriﬁed from condi-
tioned medium using a HisTrap HP column (GE Healthcare,
Piscataway, NJ, USA) as described [12]. Puriﬁed proteins were sep-
arated by sodium dodecyl sulfate–polyacrylamide gel electropho-
resis (SDS–PAGE) and visualized with Coomassie brilliant blue
(CBB) R-250 staining.
The recombinant C-terminal region of NELL1 was produced
using the LEXSYcon2 Expression kit (Jena Bioscience) according
to the manufacturer’s instructions. Brieﬂy, the pLEXSY-Neo2-
hNELL1-C plasmid was transfected into L. tarentolae by electropor-
ation, and stable transfectants were selected with G418 (50 lg/ml).
The recombinant strain was cultured in brain–heart-infusion based
medium supplemented with hemin (5 lg/ml), penicillin (50 U/ml)
and streptomycin (50 lg/ml) at 26 C in the dark with shaking
(140 rpm). Recombinant protein was puriﬁed from conditioned
medium using an Ni Sepharose 6 Fast Flow column (GE
Healthcare).
Recombinant NELL1 fragments were expressed in Escherichia
coli Rosetta-gami 2 (DE3) pLysS strain (Merck, Darmstadt, Ger-
many). E. coli cells carrying pCold-TF expression vectors were cul-
tured at 37 C until the OD600 reached 0.5, and expression of the
recombinant proteins was then induced by cold shock at 15 C
for 24 h in the presence of 1 mM isopropyl-b-D-thiogalactopyrano-
side. The cells were harvested and lysed with BugBuster HT reagent
(Novagen, Madison, WI, USA). The extracted proteins were puriﬁed
on an Ni Sepharose 6 Fast Flow column (GE Healthcare).
2.5. Cell adhesion assay
Cell adhesion assays were performed using 96-well microtiter
plates (Maxisorp; Nunc, Roskilde, Denmark). Brieﬂy, plates were
coated with the indicated concentration of NELL1 or its deletion
mutants at 4 C overnight and then blocked with 1% bovine serum
albumin (BSA) for 1 h at room temperature. Cells were harvested
with 1 mM ethylenediaminetetraacetic acid (EDTA) or TrypLE Se-
lect solution (Invitrogen), suspended in serum-free DMEM at a
density of 3  105 cells/ml, and then plated at 3  104 cells/well.
After incubation in a CO2 incubator at 37 C for 1 h, non-adherent
cells were washed from wells, and adherent cells were ﬁxed and
stained for 30 min with 0.4% (w/v) crystal violet in 50% (v/v) meth-
anol. After washing with distilled water, attached cells were
counted by microscopic examination of random ﬁelds in two
independent wells. For adhesion inhibition assays, the cells were
pre-incubated with EDTA (5 mM), peptides (10–100 lM), or
function-blocking anti-integrin antibodies (5 lg/ml) for 20 min at
room temperature before inoculation.
2.6. Immunoblot analysis
Sub-conﬂuent C3H10T1/2 cells were subjected to serum starva-
tion for 18 h. The cells were treated with NELL1 (0–10 nM) in ser-
um-free DMEM for 20 min at 37 C, and lysed with CelLytic M Cell
Lysis Reagent (Sigma, St. Louis, MO, USA) containing 1 PhosSTOP
Fig. 1. Cell-adhesive activity of recombinant NELL1. (A and B) Dose-dependent adhesion of osteoblastic cells to NELL1. Puriﬁed NELL1 was coated onto 96-well plates at the
indicated concentrations. MC3T3-E1 and Saos-2 cells were allowed to adhere for 1 h at 37 C. Non-adherent cells were washed from the wells, and adherent cells were then
ﬁxed and stained with crystal violet. (A) Representative images of cells adhering to NELL1. (B) Cell number per area adhering to NELL1. (C) Cell-type speciﬁcity of adhesion to
NELL1. NELL1 was coated at 100 nM and U2OS, MG-63, C3H10T1/2, HT-1080 and HeLa cells were allowed to adhere for 1 h at 37 C. Each value represents the mean
(±standard error) of triplicate results.
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tein samples were separated on SDS–polyacrylamide gels and
transferred onto Hybond ECL nitrocellulose membranes (GE
Healthcare). The membranes were blocked with 2% (w/v) BSA in
Tris-buffered saline (TBS) containing 0.1% (v/v) Tween-20, followed
by incubation with primary antibodies (1:1000) in Can Get Signal
immunoreaction enhancer solution 1 (Toyobo, Osaka, Janan) at
4 C overnight. The membranes were then washed with TBS con-
taining 0.1% Tween-20 and incubated with horseradish peroxi-
dase-conjugated secondary antibodies (1:5000; GE Healthcare) in
Can Get Signal solution 2 (Toyobo) at room temperature for 1 h.
The membranes were developed using ECL Prime Western Blotting
Detection Reagents (GE Healthcare) and imaged on an LAS-
4000mini Luminescent Image Analyzer (GE Healthcare).
3. Results and discussion
3.1. Cell-adhesive activities of recombinant NELL1
Cell-adhesive activity of NELL1 was examined using the mouse
MC3T3-E1 pre-osteoblast cell line and the human Saos-2 osteosar-
coma cell line. Full-length NELL1 induced the adhesion of both cell
lines in a dose-dependent manner, with maximal adhesion at aNELL1-coating concentration of approx. 100 nM (Fig. 1A & B). This
cell-adhesive activity of NELL1 is comparable to that of thrombo-
spondin-1 for several cell lines [14]. MC3T3-E1 cells displayed an
elongated and well-spread morphology, while Saos-2 cells were
less well spread (Fig. 1A). The human osteosarcoma cell lines,
U2OS and MG-63, and the mouse C3H10T1/2 mesenchymal cell
line, which can be induced to differentiate into osteoblast-like
cells, also adhered well to NELL1, while human ﬁbrosarcoma HT-
1080 and human cervical carcinoma HeLa cells showed minimal
or no adhesive activity (Fig. 1C). These results suggest that NELL1
promotes cell adhesion in a cell-type speciﬁc manner. Because
the osteoblast is of mesenchymal origin, NELL1 may be an adhe-
sion molecule for mesenchymal stem cells and osteoblastic cells.
3.2. The C-terminal region of NELL1 promotes cell adhesion
To determine which domain was responsible for promoting cell
adhesion, the C-or N-terminally truncated NELL1 constructs,
NELL1-N and NELL1-C, were generated (Fig. 2A). These truncated
proteins were expressed in mammalian 293-F cells; however, the
NELL1-C protein was degraded soon after its secretion into the cul-
ture medium. Therefore, the NELL1-C protein was expressed in
cells of the lower eukaryote L. tarentolae, because the L. tarentolae
AB C
Fig. 2. C-terminal region of NELL1 promotes MC3T3-E1 cell adhesion. (A) Schematic representations of the NELL1 proteins. A full-length NELL1 protein (NELL1-FL) contains
one TSPN domain, one coiled-coil (CC) domain, four vonWillebrand factor type C (VWC) domains, and six epidermal growth factor (EGF)-like domains. The VWC and EGF-like
domains were deleted to generate a C-terminally truncated protein (NELL1-N). The TSPN and CC domains were deleted to generate an N-terminally truncated protein (NELL1-
C). (B) NELL1-FL and NELL1-N were expressed in 293-F cells, and NELL1-C was expressed in L. tarentolae cells. The puriﬁed proteins were resolved by SDS–PAGE and visualized
by CBB staining. Molecular weight markers (M) are indicated to the left. (C) NELL1-FL and its deletion mutants were coated onto 96-well plates at a concentration of 50 nM,
and MC3T3-E1 cells were allowed to adhere for 1 h at 37 C. Each value represents the mean (± standard error) of triplicate results.
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type post-translational modiﬁcation of recombinant eukaryotic
proteins [15]. Full-length NELL1 (NELL1-FL) and its truncated
proteins were puriﬁed to near homogeneity with nickel-chelate
afﬁnity chromatography as determined by CBB staining of
SDS–polyacrylamide gels (Fig. 2B). The adhesive activity of these
proteins was evaluated using MC3T3-E1 cells (Fig. 2C). NELL1-C
displayed similar adhesive activity to NELL1-FL. In contrast,
NELL1-N showed minimal adhesion activity even at higher coating
concentrations up to 200 nM (data not shown). These results
suggest that the cell-adhesive activity of NELL1 is encoded in the
C-terminal region of NELL1 obtained from a L. tarentolae host.
To further localize the cell-binding region of the NELL1 pro-
tein, a series of NELL1 fragments were prepared as fusion pro-
teins with a hexahistidine-tag and a trigger factor (TF) as a
soluble tag (Fig. 3A). These NELL1 fragments were successfully
expressed as soluble monomer proteins in E. coli and puriﬁed
by nickel-chelate afﬁnity chromatography (Fig. 3B). The adhesive
activity of these proteins was evaluated using MC3T3-E1 cells
(Fig. 3C). Although no fragments showed adhesive activity at a
coating concentration of 50 nM (data not shown), three frag-
ments within the C-terminal region of NELL1 – N-VWC, EGF,
and C-VWC – displayed cell-adhesive activity at a coating
concentration of 500 nM. The N-terminal region of NELL1
(TSPN-CC) again showed no adhesive activity. These results
demonstrated that at least three cell-binding sites were localized
to the C-terminal region of NELL1.Recently, Nakamoto’s group reported that NELL2, a NELL family
protein predominantly expressed in the nervous system, binds to
retinal axons through the TSPN and VWC domains independently
[16]. NELL1 is also expressed in the nervous system, and it has been
shown to have a weaker binding activity to retinal axons. Further
studies will be required to identify the cell-binding sequence in
NELL1 for other cell types as well as osteoblastic cells.
NELL1-deﬁcient mice resulted in decreased bone mineraliza-
tion along with reduced expression of genes for ECM proteins crit-
ical for chondrogenesis and osteogenesis [17]. In contrast,
overexpression of NELL1 gene in MC3T3-E1 cells resulted in in-
creased osteoblast differentiation along with up-regulation of
some sets of genes for ECM proteins [18]. The functional relation-
ship between cell adhesion to NELL1 and osteogenic activity with
the production of ECM proteins remains to be determined.
Whether NELL1 fragments still have osteogenic activity is cur-
rently being investigated.
3.3. Integrin a3b1 mediates the adhesion of osteoblastic cells to NELL1
Integrins represent the major family of adhesion receptors for
ECM proteins [19]. Because integrin–ligand binding is divalent cat-
ion-dependent, we examined the effect of the divalent cation che-
lator, EDTA, on the adhesion of MC3T3-E1 and Saos-2 cells to
NELL1 (Fig. 4A). Adhesion of both cell lines to NELL1 was com-
pletely inhibited in the presence of 5 mM EDTA, suggesting that
adhesion of these cells to NELL1 is mediated by integrins.
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tion-blocking monoclonal antibodies against integrin subunits
was tested for their ability to inhibit cell adhesion to NELL1. Be-
cause these antibodies were raised against human integrins, the
inhibition assay was performed using human Saos-2 cells. Adhe-
sion to NELL1 was signiﬁcantly blocked by antibodies to the inte-
grin a3 and b1 subunits, suggesting that integrin a3b1 is
involved in the adhesion of Saos-2 cells to NELL1 (Fig. 4B). To con-
ﬁrm these results, cell adhesion to NELL1 was examined in the
presence of the synthetic peptide GD-6 containing a recognition
site for integrin a3b1 [20]. Adhesion of MC3T3-E1 cells to NELL1
was dose-dependently inhibited by GD-6 peptide but not by CS1
peptide containing a recognition site for integrin a4b1 (Fig. 4C)
[21]. These results further indicated that integrin a3b1 is the major
cellular receptor necessary for cell adhesion onto NELL1.
Integrin a3b1 is widely expressed on nearly all cell types
including osteoblastic cells and mesenchymal stem cells, which
displayed cell-adhesive activity to NELL1 (see Fig. 1C) [22–25].
However, HT-1080 and HeLa cells showed minimal or no adhesive
activity in spite of their expression of integrin a3b1 [26]. Integrin
a3b1 is known to interact with the tetraspanin family of trans-
membrane proteins [27]. For example, tetraspanin CD151 forms
a stable complex with integrin a3b1 and modulates the ligand-
binding activity of integrin a3b1 [28]. Some integrins associate
with receptor tyrosine kinases to regulate signaling pathways
cooperatively [29]. Taken together, our results suggest theexistence of a speciﬁc co-receptor for NELL1 in osteoblastic cells
and mesenchymal stem cells.
3.4. NELL1 induces phosphorylation of FAK and ERK1/2
Integrin-mediated cell adhesion activates various protein tyro-
sine kinases including FAK, which is directly activated by b1-inte-
grin signaling and leads to the association of integrins with the
cytoskeleton [30]. The FAK signaling pathway can subsequently
activate MAPK cascades to elicit speciﬁc biological responses. The
FAK-MAPK signaling pathway has been shown to be an important
mediator of laminin-332-induced osteogenic differentiation of
mesenchymal stem cells via integrin a3b1 [5]. Because NELL1
transduces osteogenic signals through MAPK cascades [11], we
investigated the FAK-MAPK pathway as the possible mechanism
of NELL1 signaling. To determine whether NELL1 induces tyrosine
phosphorylation of FAK, C3H10T1/2 cells were treated with NELL1
for 20 min. As shown in Fig. 5, NELL1 treatment resulted in in-
creased FAK phosphorylation levels relative to total FAK proteins.
Incubation of NELL1 with C3H10T1/2 cells also resulted in a similar
activation of the MAPK family member, ERK1/2. Based on the den-
sitometric intensities of the bands, the amounts of phosphorylated
FAK and ERK1/2 were estimated to have increased by 2.5- and 5.2-
folds, respectively, as compared to the untreated control cells.
These results indicate that NELL1 can induce FAK and ERK1/2 acti-
vation, probably via integrin receptors. Neither MC3T3-E1 nor
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A. Hasebe et al. / FEBS Letters 586 (2012) 2500–2506 2505Saos-2 cells showed activation of FAK under the conditions inves-
tigated in this study (data not shown). This may be due to the
osteoblastic differentiation state of these cell lines.
In summary, we have demonstrated that NELL1 promoted
osteoblastic cell adhesion via at least three cell-binding sites with-
in its C-terminal region. One of the cell surface receptors for NELL1
was determined to be integrin a3b1. Collectively, our results sug-
gest that NELL1 is a matricellular protein that modulates osteoblast
differentiation via the integrin-FAK-MAPK pathway.
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